Association of atherogenic low-density lipoprotein subfractions with carotid atherosclerosis

QJM: An International Journal of Medicine

Volumn 91, Issue 5, 1998, Pages 345-351

  Landray, M J ^a,c   Sagar, G ^a   Muskin, J ^a   Murray, S ^a   Holder, R L ^b   Lip, G Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHYLOMICRON; LOW DENSITY LIPOPROTEIN;

ADULT; AGE; AGED; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CAROTID ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOPPLER FLOWMETRY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; SMOKING; STROKE; ULTRACENTRIFUGATION;

EID: 0031902850     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/91.5.345     Document Type: Article

References (48)

1. Fabris F, Zanocchi M, Bo M, Fonte G, Poli L, Bergoglio I, Ferrario E, Pernigotti L. Carotid plaque, ageing, and risk factors. A study of 457 subjects. Stroke 1994; 25:1133-40.
2. Homer D, Ingall TJ, Baker HL Jr, O'Fallon WM, Kottke BA, Whisnant JP. Serum lipids and lipoproteins are less powerful predictors of extracranial carotid artery atherosclerosis than are cigarette smoking and hypertension. Mayo Clinic Proc; 66:259-67.
3. Sutton-Tyrrell K, Alcorn HG, Wolfson SK Jr, Kelsey SF, Kuller LH. Predictors of carotid stenosis in older adults with and without isolated systolic hypertension. Stroke 1993; 24:355-61.
4. O'Leary DH, Anderson KM, Wolf PA, Evans JC, Poehlman HW. Cholesterol and carotid atherosclerosis in older persons: the Framingham Study. Ann Epidemiol 1992; 2:147-53.
5. Postiglione A, Rubba P, De Simone B, Patti L, Cicerano U, Mancini M. Carotid atherosclerosis in familial hypercholesterolaemia. Stroke 1985; 16:658-61.
6. Lindenstrom E, Boysen C, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. Br Med J 1994; 309:11-15.
7. Heiss C, Sharrett AR, Barnes R, Chambless LE, Szklo M, Alzola C. Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol 1991; 134:250-6.
8. Ford CS, Crouse JR 3rd, Howard G, Toole JF, Ball MR, Frye J. The role of plasma lipids in carotid bifurcation atherosclerosis. Ann Neurol 1985; 17:301-3.
9. Austin MA, King M-C, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82:495-506.
10. Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994; 5:339-49.
11. Packard CJ. Plasma lipid and lipoprotein metabolism in the 1990s - what we know and what we need to know. In: Betteridge DJ, ed. Lipids: Current Perspectives. London, Martin Dunitz, 1996:1-21.
12. Packard CJ. LDL subfractions and atherogenicity: an hypothesis from the University of Glasgow. Curr Med Res Opin 1996; 13:379-90.
13. Dejager S, Bruckert E, Chapman MJ. Dense LDL sub-species with diminished oxidative resistance predominate in combined hyperlipidaemia. J Lipid Res 1993; 34:295-308.
14. Hurt-Camejo E, Camejo G, Rosengreen B, Lopez F, Wiklund O, Bonjers G. Differential uptake of proteoglycan selected subfractions of LDL by human macrophages. J Lipid Res 1990; 31:1387-98.
15. Nordestgaard BG, Nielsen LB. Atherosclerosis and arterial influx of lipoproteins. Curr Opin Lipidol 1994; 4:252-7.
16. de Graaf J, Hak-Lemmers HLM, Hectors MPL, Demacker PNM, Hendriks JCM, Stalenhoef AFH. Enhanced susceptibility to in vitro oxidation in healthy subjects. Arterioscler Thromb 1991; 11:298-306.
17. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates the uptake and degradation of acetylated low-density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 1979; 76:333-7.
18. Steinberg D, Parsatharathy S, Carew T, Khoo J, Witztum J. Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320:915-24.
19. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. Modification of low-density lipoproteins by endothelial cells involves lipid peroxidation and degradation of low-density lipoprotein phospholipids. Proc Natl Acad Sci USA 1984; 83:3883-7.
20. Rajman I, Maxwell S, Cramb R, Kendall MJ. Particle size: the key to the atherogenic lipoprotein? Q J Med 1994; 87:709-20.
21. Rajman I, Kendall MJ, Cramb R, Holder RL, Salih M, Gammage MD. Investigation of low density lipoprotein subfractions as a coronary risk factor in normotriglyceridaemic men. Atherosclerosis 1996; 125:231-42.
22. Campos H, Genest JJ, Blijlevens E, McNaamara JR, Jenner JL, Ordovas JM, Wilson PWF, Schaefer EJ. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 1992; 12:187-95.
23. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein sub-class patterns and risk of myocardial infarction. JAMA 1988; 26:1917-21.
24. Coresh J, Kwiterovich PO, Smith HH, Bachorik PS. Association of plasma triglyceride concentration and LDL particle diameter, density and chemical composition with premature coronary artery disease in men and women. J Lipid Res 1993; 34:1687-97.
25. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, Shepherd J. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994; 106:241-53.
26. Tornvall P, Karpe F, Carlson LA, Hamsten A. Relationships of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction. Atherosclerosis 1991; 90:67-80.
27. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. J Am Med Assoc 1996; 276:875-81.
28. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276:882-8.
29. Petrie J, Jamieson M, O'Brien E, Littler W, Padfield P, de Swiet M, for the Working Party on Blood Pressure Measurement. Blood Pressure Measurement [videotape]. London, BMJ Publications, 1990.
30. Carlson K. Lipoprotein fractionation. J Clin Pathol 1973; 26(Suppl. 5):32-7.
31. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project 1981-86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage. J Neurol Nerurosurg Psychiat 1990; 53:16-22.
32. James A. News: Stroke treatment trials yield disappointing results. Lancet 1997; 349:1673.
33. Wilterdink JL, Easton JD. Vascular event rates in patients with atherosclerotic cerebrovascular disease. Arch Neurol 1992; 49:857-63.
34. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. European Carotid Surgery Trialists' Collaborative Group. Lancet 1991; 337:1235-43.
35. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991; 325:445-53.
36. MRC European Carotid Surgery Trial. Endarterectomy for moderate symptomatic carotid stenosis: interim results from the MRC European Carotid Surgery Trial. Lancet 1996; 347:1591-3.
37. Matzsch T, Bergqvist D, Lindh M, Maly P, Takolander R. Natural history of patients with unoperated atherosclerotic carotid artery disease - results form a retrospective study. Eur J Vasc Surg 1993; 7:166-70.
38. Olgren M, Hedblad B, lsacsson SO, Janzon L, Jungquist G, Lindell SE. Ten year cerebrovascular morbidity and mortality in 68 year old men with asymptomatic carotid stenosis. Br Med J 1995; 310:1294-8.
39. Coresh J, Kwiterovich PO Jr. Small, dense low-density lipoprotein particles and coronary heart disease risk. A clear association with uncertain implications. JAMA 1996; 276:914-15.
40. Hodis HN, Mack WJ, Dunn M, et al. Intermediate-density lipoproteins and progression of carotid arterial wall intimamedia thickness. Circulation 1997; 95:2022-6.
41. Heller F, Harvengt C. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects. Eur J Clin Pharmacol 1983; 25:57-63.
42. Gaw A, Packard CJ, Caslake MJ, Griffin BA, Lindsay GM, Thomson J, Vallance BD, Wosornu D, Shepherd J. Effects of ciprofibrate on LDL metabolism in man. Atherosclerosis 1994; 108:137-48.
43. Caslake MJ, Packard CJ, Gaw A, et al. Fenofibrate and metabolic heterogeneity in hypercholesterolaemia. Arterioscler Thromb 1993; 13:702.
44. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992; 85:37-45.
45. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317:1237-45.
46. Cheung MC, Austin MA, Moulin P, et al. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primaryhypercholesterolaemia. Atherosclerosis 1993; 102:107-19
47. Yuan J, Tsai MY, Hegland J, Hunninghake DB. Effects of fluvastatin (XW 62-320) on HMG-CoA reductase inhibitor on the distribution and composition of LDL subspecies in humans. Atherosclerosis 1991; 87:147-53.
48. Bakker-Arkema RC, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996; 275:128-33.